{
 "as_of": "2026-11-11",
 "cmr": "fr-cm-kg/XPAR/FR0012127173",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# OSE IMMUNOTHERAPEUTICS (Euronext Paris: FR0012127173) — research page\n\nAs of 2026-11-11 · fr-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is OSE IMMUNOTHERAPEUTICS, listed on Euronext Paris under ticker FR0012127173, ISIN FR0012127173, LEI 969500HIUWVGY6NZSM05. Its security type is Corporate, its segment is not on the record, its sector is NAF 72.11Z, and its jurisdiction is France (RCS-registered SA à conseil d'administration (s.a.i.)). The listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 24 filings in the twelve months to 2026-11-11, across 18 filing days. The median gap between filing days is 6 days. The latest filing is dated 2026-11-02, 9 days before the record date, and is of type regulatory_filing. The exchange median is 8.5 days cadence, 15.0 filings and 7 days latency across 316 issuers. The sector median is 8.0 days cadence, 20.0 filings and 7.0 days latency across 24 issuers.\n\n## Auditor\n\nThe auditor of record is not on the record. The record carries the annual report link only, and the auditor's location and any auditor changes are not on the record.\n\n## Events and halts\n\nThe listing, delisting, name change, domicile change and segment move lifecycle lines are not on the record, as the index does not carry a lifecycle type map for this register. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe orderability outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/fr/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe issuer's own investor-relations page names 4 research houses: Edison, Invest Securities, Kepler Cheuvreux and Edison Securities.\n\n## Open research\n\nThe record holds 5 openly published research notes, all by Edison Investment Research: dated 2025-08-29, 2025-06-05, 2024-11-21, 2023-12-12 and 2023-05-24.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record began is not on the record.\n\n## Sources\n\n13 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://registers.esma.europa.eu/publication/searchRegister?core=esma_registers_firds (identity.exchange)\n- https://recherche-entreprises.api.gouv.fr/search?q=479457715 (identity.jurisdiction)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.fr-cm-kg.ai/events/XPAR/FR0012127173 (the disclosure lines)\n- https://live.euronext.com/en/ajax/haltedInstrument/getAjax/current (the halt flag)\n- https://mcp.fr-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://www.ose-immuno.com/en/investors-2/ (coverage)\n- https://www.ose-immuno.com/wp-content/uploads/2025/08/Edison_290825.pdf (open research)\n- https://www.ose-immuno.com/wp-content/uploads/2025/06/Edison_050625.pdf (open research)\n- https://www.ose-immuno.com/wp-content/uploads/2024/11/Edison-21-November-2024.pdf (open research)\n- https://www.ose-immuno.com/wp-content/uploads/2023/12/Edison-note-121223.pdf (open research)\n- https://www.ose-immuno.com/wp-content/uploads/2023/09/Edison-240523.pdf (open research)\n- https://mcp.fr-cm-kg.ai/record/XPAR/FR0012127173 (the record)\n",
 "market": "FR",
 "node": "fr-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": null,
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "the FR vintage is not sealed; the record is the live record as of 2026-11-11",
   "record_version": 1,
   "sealed": false
  },
  "auditor": {
   "auditor": {
    "market": "FR",
    "reason": "Width 0 records the annual report link only (ORDER-016: source link, not a read)",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "FR",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "FR",
    "state": "not_on_record"
   },
   "changes": {
    "market": "FR",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "cmr": "fr-cm-kg/XPAR/FR0012127173",
  "coverage": {
   "count": 4,
   "houses": [
    {
     "analyst": "Arron Aatkar",
     "house": "Edison",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://www.ose-immuno.com/en/investors-2/",
     "state": "sourced"
    },
    {
     "analyst": "Jamila El Bougrini",
     "house": "Invest Securities",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://www.ose-immuno.com/en/investors-2/",
     "state": "sourced"
    },
    {
     "analyst": "Pierre-Alexandre Desir",
     "house": "Kepler Cheuvreux",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://www.ose-immuno.com/en/investors-2/",
     "state": "sourced"
    },
    {
     "analyst": "Arron Aatkar",
     "house": "Edison Securities",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://www.ose-immuno.com/en/investors-2/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://www.ose-immuno.com/en/investors-2/",
     "result": "read: 4 of 6 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 316,
     "median_cadence_gap_days": 8.5,
     "median_filings": 15,
     "median_latency_days": 7,
     "name": "Euronext Paris"
    },
    "sector": {
     "issuers": 24,
     "median_cadence_gap_days": 8,
     "median_filings": 20,
     "median_latency_days": 7,
     "name": "NAF 72.11Z"
    }
   },
   "by_type": {
    "directors_dealings": 1,
    "newswire_release": 16,
    "prospectus": 1,
    "regulatory_filing": 6
   },
   "cadence_median_gap_days": 6,
   "filing_days": 18,
   "filings": 24,
   "latency_days": 9,
   "latest": [
    {
     "category": "VAD",
     "date": "2026-11-02",
     "source": "https://bdif.amf-france.org/#/information/2026E1147846",
     "title": "DeclarationPositionsCourtes [VAD]",
     "type": "regulatory_filing"
    },
    {
     "category": null,
     "date": "2026-10-29",
     "source": "https://www.globenewswire.com/news-release/2026/10/29/3391736/0/fr/ose-immunotherapeutics-annonce-des-r%C3%A9sultats-positifs-compl%C3%A9mentaires-de-l-%C3%A9tude-de-phase-2-randomis%C3%A9e-combi-ted-de-tedopi-ose2101-dans-le-cancer-du-poumon-non-%C3%A0-petites-cellules-m.html",
     "title": "OSE Immunotherapeutics annonce des résultats positifs",
     "type": "newswire_release"
    },
    {
     "category": null,
     "date": "2026-10-29",
     "source": "https://www.globenewswire.com/news-release/2026/10/29/3391736/0/en/ose-immunotherapeutics-reports-additional-positive-results-of-combi-ted-phase-2-randomized-trial-with-tedopi-ose2101-in-metastatic-non-small-cell-lung-cancer.html",
     "title": "OSE Immunotherapeutics Reports Additional Positive Results",
     "type": "newswire_release"
    },
    {
     "category": "VAD",
     "date": "2026-10-28",
     "source": "https://bdif.amf-france.org/#/information/2026E1146866",
     "title": "DeclarationPositionsCourtes [VAD]",
     "type": "regulatory_filing"
    },
    {
     "category": "VAD",
     "date": "2026-10-23",
     "source": "https://bdif.amf-france.org/#/information/2026E1146075",
     "title": "DeclarationPositionsCourtes [VAD]",
     "type": "regulatory_filing"
    }
   ],
   "latest_filing_date": "2026-11-02",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.fr-cm-kg.ai/events/XPAR/FR0012127173",
   "window": {
    "from": "2025-11-11",
    "to": "2026-11-11"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "ESMA FIRDS full equity file (EU instrument reference data per trading venue)",
    "read_date": "2026-11-11",
    "read_date_basis": "the record version as_of",
    "source": "https://registers.esma.europa.eu/publication/searchRegister?core=esma_registers_firds (FIRDS full equity files 2026-09-05)",
    "state": "sourced",
    "value": "Euronext Paris"
   },
   "isin": {
    "read_by": "ESMA FIRDS full equity file (EU instrument reference data per trading venue)",
    "read_date": "2026-11-11",
    "read_date_basis": "the record version as_of",
    "source": "https://registers.esma.europa.eu/publication/searchRegister?core=esma_registers_firds (FIRDS full equity files 2026-09-05)",
    "state": "confirmed",
    "value": "FR0012127173"
   },
   "jurisdiction": {
    "read_by": "French State company search (recherche-entreprises.api.gouv.fr; INSEE / RNE register data) (nature juridique)",
    "read_date": "2026-11-11",
    "read_date_basis": "the record version as_of",
    "source": "https://recherche-entreprises.api.gouv.fr/search?q=479457715",
    "state": "sourced",
    "value": "France (RCS-registered SA à conseil d'administration (s.a.i.))"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-12",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN FR0012127173)",
    "state": "sourced",
    "value": "969500HIUWVGY6NZSM05"
   },
   "name": {
    "read_by": "ESMA FIRDS full equity file (EU instrument reference data per trading venue)",
    "read_date": "2026-11-11",
    "read_date_basis": "the record version as_of",
    "source": "https://registers.esma.europa.eu/publication/searchRegister?core=esma_registers_firds (FIRDS full equity files 2026-09-05)",
    "state": "sourced",
    "value": "OSE IMMUNOTHERAPEUTICS"
   },
   "sector": {
    "read_by": "French State company search (recherche-entreprises.api.gouv.fr; INSEE / RNE register data) (activité principale, NAF)",
    "read_date": "2026-11-11",
    "read_date_basis": "the record version as_of",
    "source": "https://recherche-entreprises.api.gouv.fr/search?q=479457715",
    "state": "sourced",
    "value": "NAF 72.11Z"
   },
   "security_type": {
    "read_by": "ESMA FIRDS full equity file (EU instrument reference data per trading venue)",
    "read_date": "2026-11-11",
    "read_date_basis": "the record version as_of",
    "source": "https://registers.esma.europa.eu/publication/searchRegister?core=esma_registers_firds (FIRDS full equity files 2026-09-05)",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "FR",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "ESMA FIRDS full equity file (EU instrument reference data per trading venue)",
    "read_date": "2026-11-11",
    "read_date_basis": "the record version as_of",
    "source": "https://registers.esma.europa.eu/publication/searchRegister?core=esma_registers_firds (FIRDS full equity files 2026-09-05)",
    "state": "sourced",
    "value": "FR0012127173"
   },
   "website": {
    "market": "FR",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": {
    "market": "FR",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "domicile_change": {
    "market": "FR",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "listing": {
    "market": "FR",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "name_change": {
    "market": "FR",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "segment_move": {
    "market": "FR",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "market": "FR",
  "node": "fr-cm-kg",
  "numbers_hash": "sha256:0e5bc89fbb48c3477a009cafbccbb6e07ee3f185e4406a362beb6fcb8f447040",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [
    {
     "date": "2025-08-29",
     "kind": "issuer-sponsored",
     "publisher": "Edison Investment Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://www.ose-immuno.com/wp-content/uploads/2025/08/Edison_290825.pdf",
     "state": "sourced",
     "title": "Spotlight on OSE's diverse clinical pipeline"
    },
    {
     "date": "2025-06-05",
     "kind": "issuer-sponsored",
     "publisher": "Edison Investment Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://www.ose-immuno.com/wp-content/uploads/2025/06/Edison_050625.pdf",
     "state": "sourced",
     "title": "New UC biomarker underpins growth strategy"
    },
    {
     "date": "2024-11-21",
     "kind": "issuer-sponsored",
     "publisher": "Edison Investment Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://www.ose-immuno.com/wp-content/uploads/2024/11/Edison-21-November-2024.pdf",
     "state": "sourced",
     "title": "OSE Immunotherapeutics"
    },
    {
     "date": "2023-12-12",
     "kind": "issuer-sponsored",
     "publisher": "Edison Investment Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://www.ose-immuno.com/wp-content/uploads/2023/12/Edison-note-121223.pdf",
     "state": "sourced",
     "title": "OSE Immunotherapeutics"
    },
    {
     "date": "2023-05-24",
     "kind": "issuer-sponsored",
     "publisher": "Edison Investment Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://www.ose-immuno.com/wp-content/uploads/2023/09/Edison-240523.pdf",
     "state": "sourced",
     "title": "Re-initiation of coverage — Milestones anticipated throughout FY23"
    }
   ],
   "state": "found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.fr-cm-kg.ai/book/aio.json",
    "door": "https://mcp.fr-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/fr/mifid-ii-product-governance/r1",
   "section": "fr.aio.v10"
  },
  "record": {
   "as_of": "2026-11-11",
   "url": "https://mcp.fr-cm-kg.ai/record/XPAR/FR0012127173",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-12",
   "source": "https://live.euronext.com/en/ajax/haltedInstrument/getAjax/current",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:0e5bc89fbb48c3477a009cafbccbb6e07ee3f185e4406a362beb6fcb8f447040",
 "path": "/fr/XPAR/FR0012127173",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is OSE IMMUNOTHERAPEUTICS, listed on Euronext Paris under ticker FR0012127173, ISIN FR0012127173, LEI 969500HIUWVGY6NZSM05. Its security type is Corporate, its segment is not on the record, its sector is NAF 72.11Z, and its jurisdiction is France (RCS-registered SA à conseil d'administration (s.a.i.)). The listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 24 filings in the twelve months to 2026-11-11, across 18 filing days. The median gap between filing days is 6 days. The latest filing is dated 2026-11-02, 9 days before the record date, and is of type regulatory_filing. The exchange median is 8.5 days cadence, 15.0 filings and 7 days latency across 316 issuers. The sector median is 8.0 days cadence, 20.0 filings and 7.0 days latency across 24 issuers.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is not on the record. The record carries the annual report link only, and the auditor's location and any auditor changes are not on the record.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The listing, delisting, name change, domicile change and segment move lifecycle lines are not on the record, as the index does not carry a lifecycle type map for this register. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The orderability outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/fr/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's own investor-relations page names 4 research houses: Edison, Invest Securities, Kepler Cheuvreux and Edison Securities.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "The record holds 5 openly published research notes, all by Edison Investment Research: dated 2025-08-29, 2025-06-05, 2024-11-21, 2023-12-12 and 2023-05-24.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record began is not on the record.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "13 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://registers.esma.europa.eu/publication/searchRegister?core=esma_registers_firds"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://recherche-entreprises.api.gouv.fr/search?q=479457715"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.fr-cm-kg.ai/events/XPAR/FR0012127173"
  },
  {
   "for": "the halt flag",
   "source": "https://live.euronext.com/en/ajax/haltedInstrument/getAjax/current"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.fr-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://www.ose-immuno.com/en/investors-2/"
  },
  {
   "for": "open research",
   "source": "https://www.ose-immuno.com/wp-content/uploads/2025/08/Edison_290825.pdf"
  },
  {
   "for": "open research",
   "source": "https://www.ose-immuno.com/wp-content/uploads/2025/06/Edison_050625.pdf"
  },
  {
   "for": "open research",
   "source": "https://www.ose-immuno.com/wp-content/uploads/2024/11/Edison-21-November-2024.pdf"
  },
  {
   "for": "open research",
   "source": "https://www.ose-immuno.com/wp-content/uploads/2023/12/Edison-note-121223.pdf"
  },
  {
   "for": "open research",
   "source": "https://www.ose-immuno.com/wp-content/uploads/2023/09/Edison-240523.pdf"
  },
  {
   "for": "the record",
   "source": "https://mcp.fr-cm-kg.ai/record/XPAR/FR0012127173"
  }
 ],
 "title": "OSE IMMUNOTHERAPEUTICS (FR0012127173) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}